Rheumatoid arthritis By Dr Luke Bereznicki
|
|
- Allyson Gregory
- 6 years ago
- Views:
Transcription
1 Rheumatoid arthritis By Dr Luke Bereznicki Learning objectives After reading this article you should be able to: Discuss the importance of early diagnosis and treatment of rheumatoid arthritis Discuss the role of diseasemodifying anti-rheumatic drugs in managing rheumatoid arthritis Discuss the role of other pharmacological and nonpharmacological treatment options. Competency standards (2010) addressed: 4.2.2, 7.1.2, 7.1.3, Accreditation number: CAP111010e Dr Luke Bereznicki is Senior Lecturer in Pharmacy Practice and Deputy Head of School at the Tasmanian School of Pharmacy, Unit for Medication Outcomes Research and Education, School of Pharmacy, University of Tasmania. Introduction Rheumatoid arthritis is the most common autoimmune disease in Australia, affecting approximately 2% of the population. 1 It is more common in females, who tend to develop the condition at an earlier age. Disease onset most commonly occurs in people aged 35 to 64 years. 1 It is a highly disabling condition that results in disruption to family life, reduced earning capacity (around 25% of people may stop working or have reduced capacity to work at six years following diagnosis), and restricted social interaction. 2 Until the 1990s, people with rheumatoid arthritis were typically treated with non-steroidal anti-inflammatory drugs (NSAIDs) initially, with disease-modifying antirheumatic drugs (DMARDs) added as the condition worsened. The use of combinations of DMARDs was reserved for those with severe disease. Enhanced understanding of the pathophysiology of rheumatoid arthritis has led to a number of important changes to its management. These include recognition of the importance of early diagnosis and treatment, increasing use of DMARDs in combination, the development and increasing use of anti-cytokine medications, and recognition of the contribution of coexisting diseases (particularly cardiovascular disease) to the long-term outcomes for people with rheumatoid arthritis. Pathophysiology Rheumatoid arthritis is an inflammatory autoimmune disease with local and systemic manifestations. It usually affects the synovial joints initially, causing pain, swelling and stiffness. The inflammatory response involves a number of cells (e.g. T-lymphocytes, B-lymphocytes, macrophages) and cytokines (e.g. tumour necrosis factor (TNF), interleukin-1 (IL-1)). White blood cells invade the synovium 858
2 Submit your answers online at and receive automatic feedback (the secretory inner lining of joint capsules), which becomes thick and inflamed. A number of inflammatory mediators are released (including cytokines, chemokines and prostanoids) which damage surrounding bone, cartilage, tendons and ligaments and may cause systemic symptoms such as fatigue. This inflammatory process leads to functional limitations, and progresses to joint destruction (with both bony erosions and cartilage loss) and extraarticular disease (e.g. rheumatoid nodules, osteoporosis, lung fibrosis). 3 Mortality rates are higher in people with rheumatoid arthritis compared to people without the disease, presumably as a result of chronic, systemic inflammation. 4 Initial diagnosis In the past, the outcome of rheumatoid arthritis was progressive joint destruction with loss of joint function. 3 However, the aims of treatment have shifted from palliation to early induction of disease remission to prevent joint damage. 5 This is due to earlier diagnosis and treatment, new medications, and better monitoring of patients. 3 Joint damage, largely irreversible, occurs early in rheumatoid arthritis. In one study, 30% of patients had evidence of bony erosions at the time of diagnosis, and 60% at two years following diagnosis. 6 Research shows that early diagnosis and initiation of DMARDs within three months are critical. A delay of even 12 weeks in their introduction is associated with substantially greater joint damage at five years following diagnosis. 7 9 No single test or set of criteria is available to diagnose rheumatoid arthritis. A combination of clinical assessment, laboratory tests and x-rays are generally used. Joint swelling (synovitis) associated with pain or stiffness is a key diagnostic feature in early disease, along with the number of tender or swollen joint areas, and the pattern of joint involvement. 5,10 The classic pattern is symmetrical involvement of the small joints of the hands and feet. Atypical joint involvement, which occurs in some patients, presents with only one large joint affected. 11 General symptoms such as fatigue, fever, sweating and weight loss may also be present in early disease. A number of tests can be used to assist diagnosis, although the absence of positive results does not necessarily rule out rheumatoid arthritis. These include acute phase reactants (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)), full blood count and autoantibody tests (rheumatoid factor (RhF), anticyclic citrullinated peptide antibodies (anti CCP)). Initial therapy In the early stages of inflammatory arthritis, a definitive diagnosis of rheumatoid arthritis may be difficult to make. However, if rheumatoid arthritis is suspected initial therapy can be commenced. 5,10 This consists of omega-3 fatty acids at a dose of at least 2.7 g daily in divided doses (equivalent to 9 standard dose fish oil capsules), with or without paracetamol and/or an NSAID. 5 For those with severe symptoms and functional impairment or in patients at risk of NSAID adverse effects, low-dose prednisolone/ prednisone is recommended. 5 DMARDs may also be considered when there are several swollen joints, especially if autoantibody tests are positive (in conjunction with referral to a rheumatologist). 10 Other recommended interventions include: 10 Table 1. Conventional DMARDs. DMARD Efficacy* Efficacy in combination with methotrexate* Major toxicity frequency* Selected adverse effects** Recommended monitoring** Azathioprine + Unknown + Myelosuppression, hepatotoxicity FBE, U&E, LFT baseline; repeat FBE every 2 weeks until dose stable, then FBE every 1 3 months Cyclosporin Renal insufficiency, anaemia, hypertension Leflunomide Infections, diarrhoea, alopecia, rash, raised liver enzymes, headache, paraesthesia Methotrexate ++ + Myelosuppression, pulmonary infiltrates, hepatic fibrosis and cirrhosis Gold salts Rash, itch, diarrhoea (with oral gold), myelosuppression, proteinuria FBE, U&E, LFT, BP, urinalysis baseline, then U&E, BP every 2 weeks until dose stable, then every 3 months LFT, FBE, Cr, BP baseline; then every 2 4 weeks for 3 months, then every 3 months FBE, Cr, LFT baseline and dose increase; then every 2 4 weeks for 3 months, then every 3 months. PFT, chest x-ray baseline FBE, urinalysis baseline; oral: repeat each month; IM: every 1 2 weeks for the first 5 months then before each injection Hydroxychloroquine + ++ Rash, retinal damage, GI adverse effects Penicillamine Myelosuppression, proteinuria, rash, stomatitis FBE, Cr, LFT baseline and dose increase; ophthalmic exam baseline, then annually FBE and urinalysis every 2 weeks until dose stable, then every 1 3 months Sulfasalazine Myelosuppression, rash FBE, Cr, LFT baseline and dose increase; then every 2 4 weeks for 3 months, then every 3 months *Taken from Roberts et al ± scoring is a clinical guide to relative effects representing the views of the authors based on published studies. 5 **Taken from the AMH Cr= creatinine, FBE = full blood examination, LFT = liver function tests, PFT = pulmonary function tests, U&E = urea, creatinine and electrolytes 859
3 patient education and referral to support services (e.g. Arthritis Australia) exercise ice and/or heat therapy referral for enhanced primary care (e.g. physiotherapy, occupational therapy, podiatry, psychology) assessment of weight, body mass index (BMI), fatigue, sleep quality, impact on activities of daily living. Early referral Early referral of patients with suspected rheumatoid arthritis to a rheumatologist by GPs is very important. A delay in referral of > 12 weeks is associated with a reduced chance of drug-free remission and increased risk of progressive joint damage. 12 Specialist referral for advanced therapy is recommended when there is persistent swelling in multiple joints (more urgently if RhF and/or anti-ccp antibody are positive), or the patient is requiring NSAIDs or corticosteroids beyond six weeks. 10 In some cases DMARDs (e.g. methotrexate) may be commenced in consultation with a rheumatologist if immediate referral is not possible. A meta-analysis of trials demonstrated that early introduction of DMARDs prevents joint damage. 13 This is particularly important for people with more aggressive disease. The window of opportunity where the immune response is most responsive to therapy and the course of the disease can be altered may be as short as 12 weeks. 3,12 Ongoing management The prognosis for people newly diagnosed with rheumatoid arthritis has improved as the importance of early diagnosis and treatment is increasingly recognised. Most people who develop rheumatoid arthritis can now expect to have their disease well controlled and are likely to avoid longterm damage and disability. 14 The ultimate aim in treating rheumatoid arthritis is to induce complete remission. 10 If remission cannot be achieved, treatment is aimed at controlling disease activity and slowing the rate of joint damage. Other treatment goals include alleviation of pain, maintenance of function for essential activities of daily living and work, and maximisation of quality of life. DMARDs The early use of DMARDs, their use in combination, and the development of new biological DMARDs (bdmards) are seen as major advances in the management of rheumatoid arthritis and are largely responsible for the positive changes in patient outcomes. Conventional DMARDs A number of conventional DMARDs are available (see Table 1 for a comparison of available agents). Methotrexate is regarded as first-line treatment, particularly for moderate to severe disease or where there is a high risk of erosive disease. Research has found that it improves clinical and radiological outcomes; has an acceptable long-term safety profile; is acceptable to patients, with good adherence rates; and is cost-effective. 10 Leflunomide or sulfasalazine are recommended as alternatives where methotrexate is contraindicated. Hydroxychloroquine is considered an appropriate choice for mild disease. 10 The most common adverse effects of methotrexate are gastrointestinal problems and hepatic toxicity. Folic acid is recommended to reduce the risk of gastrointestinal toxicity; the suggested regimen in the Therapeutic Guidelines (Rheumatology) is 5 10 mg once weekly. 5 There is increasing evidence that combination therapy is more effective than monotherapy for many patients. The balance between benefit and risk varies among combinations. A recent meta-analysis found that methotrexate plus sulfasalazine and/or hydroxychloroquine had particularly favourable benefit/risk ratios compared to other combinations of conventional DMARDs. 15 Current Australian guidelines state that combination therapy appears to have no greater toxicity than monotherapy, although individual combinations vary in terms of toxicity. 10 Combination Table 2. Biological DMARDs. bdmard Description Selected adverse effects* Recommended monitoring* TNF-alpha inhibitors Adalimumab Humanised monoclonal antibody against TBF-alpha Infections, worsening heart failure, Certolizumab Fab fragment of a humanised TNF-alpha inhibitor monoclonal antibody blood dyscrasias, (infliximab also hypersensitivity, infusion-related Etanercept Humanised soluble recombinant TNG-alpha type II receptor-igg1 fusion protein reactions) Golimumab Infliximab Cytokine modulators Abatacept Human monoclonal antibody against TNF-alpha Chimeric mouse-human monoclonal antibody against TNF-alpha An immunoglobulin and extracellular CTLA4 domain fusion protein that selectively inhibits T-cell co-stimulation Infections, infusion-related reactions FBE, Cr, LFT baseline (also at dose increase for adalimumab and infliximab) FBE, Cr, LFT baseline Anakinra Human recombinant interleukin 1 receptor antagonist Infections, neutropenia FBE baseline Rituximab Chimeric monoclonal anti-cd20 antibody that depletes B-cells Infections, infusion-related reactions Tocilizumab Humanised monoclonal anti-interleukin 6 receptor antibody Infections, neutropenia, thrombocytopenia, hyperlipidaemia, infusion-related reactions *Taken from the AMH Cr= creatinine, FBE = full blood examination, LFT = liver function tests. FBE, Cr, LFT baseline FBE, lipids, LFT baseline, then platelets and neutrophils every 4 8 weeks; LFT every 4 8 weeks for 6 months, then 3 monthly; lipids at 4 8 weeks 860
4 therapy should be considered for those who do not respond adequately to monotherapy or may be used initially for those with a poor prognosis (e.g. high disease activity, large number of swollen joints). 5,10 Corticosteroids A low to moderate dose (7.5 mg to 15 mg) of prednisolone/prednisone is effective in reducing symptoms of rheumatoid arthritis and progression to joint destruction. 16 Intra-articular or intramuscular corticosteroids are also effective for rapid symptomatic relief. 10 Because they have a rapid onset, corticosteroids are useful as bridging therapy when DMARDs or other combination therapy are commenced. 5,10 However, they are not recommended for long-term use due to their well-known adverse effect profile (including increased cardiovascular risk, mood disturbances and osteoporosis). 5,10 Biological DMARDs The bdmards target cytokines and cells of the immune system that are involved in joint destruction (see Table 2 for a comparison of available agents). The available evidence demonstrates that the combination of methotrexate and a bdmard is superior to either drug alone at reducing symptoms and progression of joint damage in patients with early disease and those who do not respond to conventional DMARDs. 17 In Australia, their use is reserved for the treatment of rheumatoid arthritis if remission is not achieved with the appropriate use of conventional DMARDs. 5 They are all more effective when used in combination with methotrexate. 5,17 People taking bdmards are at increased risk of bacterial infection, and patients should be asked to report symptoms suggestive of infection, including fever or persistent cough. 5,18 Analgesics The use of paracetamol is recommended for managing pain in early rheumatoid arthritis, although many patients are unlikely to receive sufficient pain relief when used alone. 10 Patients should be encouraged to take paracetamol around the clock to maximise its effectiveness. If possible, paracetamol should be used instead of NSAIDs, although NSAIDs are more effective in established disease. 19 The use of regular paracetamol and fish oil (see below) is a useful way to limit the need for NSAIDs. Opioid analgesics (e.g. codeine, tramadol, oxycodone) may also be recommended when pain is interfering with patients ability to function. 20 Other options, such as amitriptyline, may also be recommended. 20 Because of their adverse effect profile (e.g. increased cardiovascular risk, gastrointestinal toxicity, hypertension) and the fact that they do not reduce joint damage, NSAIDs are not regarded as first-line treatment for rheumatoid arthritis. Their role is to reduce symptoms prior to the commencement of a DMARD. 5,21 An important practical consideration is a patient s need for chronic use of NSAIDs in rheumatoid arthritis. This can be used as a prompt to initiate more intensive therapies. 21 They should be used for the shortest duration possible at the lowest effective dose and avoided in people taking corticosteroids and/or anticoagulants. 10 Omega-3 fatty acid supplements Current guidelines recommend omega-3 fatty acid supplementation as an adjunct for pain management and relief of joint stiffness in rheumatoid arthritis. 5,10 At relatively high doses (> 2.7g per day of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), they have been shown to reduce symptoms and the need for NSAIDs, and may also provide some cardiovascular protection. 22 The benefits may take eight to 12 weeks to become fully apparent. 5 Complementary medicines There is currently insufficient evidence to support the use of complementary and alternative medicines for the management of rheumatoid arthritis, with the exception of fatty acid supplementation. 10 The Chinese herb Tripterygium wilfordii has been shown to be effective in improving the symptoms of rheumatoid arthritis. However, it is associated with significantly higher rates of serious adverse effects than placebo (e.g. impaired renal function, haematotoxicity, immunosuppressive effects). 23 Current guidelines advise against its use. 10 Non-pharmacological interventions Current Australian guidelines highlight the importance of patient knowledge and self-efficacy in the management of rheumatoid arthritis. 5,10 Patients who feel helpless regarding their condition tend to have poorer outcomes. Arthritis self-management courses are offered by Arthritis Australia and have demonstrated improved disease outcomes. 5 There is limited evidence of a beneficial effect of specific diets (e.g. gluten free, vegan, vegetarian) on patient outcomes. 24 However, it is accepted that weight reduction in patients who are overweight or obese reduces impact on weight-bearing joints and the risk of cardiovascular disease. 10 Maintaining BMI within the normal range is important, as there is evidence that patients with low BMI have poorer functional status. 25 The available evidence suggests that low to moderate intensity exercise is effective in increasing aerobic capacity and muscle strength in people with rheumatoid arthritis, with no adverse effects on pain or disease activity. 26 Cigarette smoking, in addition to increasing patients cardiovascular risk, may predispose to rheumatoid arthritis and increase disease severity. 27 An active approach to assist rheumatoid arthritis sufferers to quit is therefore important for a number of reasons. Cardiovascular risk People with rheumatoid arthritis have a higher risk of cardiovascular disease, principally due to the presence of chronic systemic inflammation. 28 The available evidence suggests that effective and sustained control of joint and systemic inflammation will reduce this excess cardiovascular risk. 28 Prevention of cardiovascular disease in rheumatoid arthritis should involve a comprehensive approach including cardiovascular risk factor screening and management, effective control of disease activity, and prompt investigation of suspected cardiac disease. 5,28 Summary There have been a number of important changes to the management of rheumatoid arthritis 862
5 Submit your answers online at and receive automatic feedback over the past 10 to15 years. Early diagnosis and treatment are critical in slowing disease progression. Early use of DMARDs, combined use of disease-modifying agents, and the use of bdmards have been critical in improving patient outcomes. Pharmacists can assist patients with rheumatoid arthritis by encouraging them to learn more about their condition; educating them about their medications (e.g. benefits and risks); assisting with monitoring for adverse effects of treatment; and providing advice on disease management using both pharmacological and non pharmacological strategies. References 1. Australian Institute of Health and Welfare. A picture of rheumatoid arthritis in Australia. Canberra: AIHW; Australian Institute of Health and Welfare. Arthritis and musculoskeletal conditions in Australia, Canberra: AIHW; Klarenbeek NB, Kerstens PJ, Huizinga TW, et al. Recent advances in the management of rheumatoid arthritis. BMJ. 2010; 341:c Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clinical and experimental rheumatology. 2008; 26:S Therapeutic Guidelines Ltd. etg Complete: Rheumatology; van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995; 34 Suppl 2: Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001; 111: Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol. 1995; 22: Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol. 2000; 27: Royal Australian College of General Practitioners. Clinical guidelines for the diagnosis and management of early rheumatoid arthritis. Melbourne: RACGP; Aletaha D, Neogi T, Silman AJ, et al rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69: van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010; 62: Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010; 69: Roberts LJ, Cleland LG, Thomas R, et al. Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. MJA. 2006; 184: Choy EH, Smith C, Dore CJ, et al. A meta-analysis of the efficacy and toxicity of combining diseasemodifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology. 2005; 44: Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet. 1997; 350: Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann Rheum Dis. 2010; 69: Gardam MA, Keystone EC, Menzies R, et al. Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003; 3: Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007; 66: Rossi S (Ed). Australian Medicines Handbook. Adelaide: AMH; Zheng Jun Cai F, Cleland L, James M. Managing arthritis and vascular disease a rheumatology perspective. Aust Prescr. 2006; 29: Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007; 129: Canter PH, Lee HS, Ernst E. A systematic review of randomised clinical trials of Tripterygium wilfordii for rheumatoid arthritis. Phytomedicine. 2006; 13: Hagen KB, Byfuglien MG, Falzon L, et al. Dietary interventions for rheumatoid arthritis. Cochrane Database of Systematic Reviews Art. No.: CD Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 2005; 165: Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, et al. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database of Systematic Reviews Art. No.: CD Saag KG, Cerhan JR, Kolluri S, et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis. 1997; 56: Van Doornum S, Jennings GL, Wicks IP. Reducing the cardiovascular disease burden in rheumatoid arthritis. MJA. 2006; 184: Questions A score of 4 out of 5 attracts 1 CPD credit. 1. The prevalence of rheumatoid arthritis in Australia is estimated to be: a) 1%. b) 2%. c) 3%. d) 4%. 2. The prognosis of rheumatoid arthritis has been improved by all of the following, EXCEPT: a) early diagnosis. b) early initiation of DMARDs. c) increased use of DMARDs in combination. d) increased use of NSAIDs. 3. The window of opportunity for initiation of DMARD treatment for rheumatoid arthritis where the immune response is most responsive to therapy and the course of the disease can be altered is thought to be: a) 4 weeks. b) 8 weeks. c) 12 weeks. d) 16 weeks. 4. Which ONE of the following DMARDs is generally regarded as the preferred first-line treatment for moderate-severe rheumatoid arthritis? a) Methotrexate. b) Leflunomide. c) Cyclosporin. d) Sulfasalazine. 5. Beneficial strategies to limit the long-term use of NSAIDs in the treatment of rheumatoid arthritis include all of the following, EXCEPT: a) regular use of paracetamol. b) fish oil supplementation. c) early initiation of DMARD therapy. d) regular use of prednisolone. 863
Rheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationDeciding what to do about Rheumatoid Arthritis
Shared Decision Making rheumatoid arthritis Next clinical review date March 2018 Deciding what to do about Rheumatoid Arthritis This short decision aid is to help you decide what treatment to have if you
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationEarly synovitis clinics
Early synovitis clinics Jeremy Jones MD FRACP FAFRM Consultant Rheumatologist, Llandudno General Hospital Honorary Research Fellow School of Sport, Health and Exercise Sciences Bangor University RA medication
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationRheumatoid Arthritis. Ajay Bhatia Rheumatology Consultant Hillingdon Hospital
Rheumatoid Arthritis Ajay Bhatia Rheumatology Consultant Hillingdon Hospital ajay.bhatia@thh.nhs.uk Rheumatoid Arthritis When to refer to secondary care? Why early referral is beneficial for the patient?
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Contents Introduction...3 What is rheumatoid arthritis?...4 Symptoms of rheumatoid arthritis... 5 What causes rheumatoid arthritis?... 10 The role of genes and family
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationInflammatory rheumatic diseases
Learning objectives Inflammatory rheumatic diseases Bruce Kidd Barts & The London, Queen Mary, University of London To understand: 1. prevalence and range of the rheumatological s 2. clinical features
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationPain or stiffness in joints after periods of inactivity or excessive use
Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed
More informationCell-Mediated Immunity and T Lymphocytes
Cell-Mediated Immunity and T Lymphocytes T helper (Th) Cells Peripheral lymhoid tissue thymus Lymphoid stem cell CD8+ CD4+ CD4+ Treg CD8+ CTL + antigen Cytotoxic T lymphocyte CD4+ Th Helper T cell CD4+
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationRheumatoid arthritis in adults
Rheumatoid arthritis in adults NICE guideline: short version Draft for consultation, September 0 This guideline offers evidence-based advice on the diagnosis and management of rheumatoid arthritis in adults.
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationRheumatoid Arthritis. Module III
Rheumatoid Arthritis Module III Management: Biological disease modifying anti-rheumatic drugs, glucocorticoids and special situations (pregnancy & lactation) Dr Ved Chaturvedi MD, DM Senior Consultant
More informationRheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationAzathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS
Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least
More informationMANAGEMENT OF EARLY RHEUMATOID ARTHRITIS
MANAGEMENT OF EARLY RHEUMATOID ARTHRITIS Dr. Majesh Pratap Malla* and Dr. She Yuan Ju Department of Orthopaedics, Clinical Medical College of Yangtze University, Jingzhou Central Hospital, Jingzhou, Hubei
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationConcordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent
Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent Michela Frendo, John Paul Caruana Galizia, Andrew A Borg Abstract Aims:
More informationDisease modifying drugs in adult rheumatoid arthritis
Disease modifying drugs in adult rheumatoid arthritis Anita T.Y. Lee and Kevin Pile, Department of Rheumatology, University of Adelaide, Queen Elizabeth Hospital, Adelaide SYNOPSIS Effective treatment
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationTo help you with terms and abbreviations used in this document that may be unfamiliar to you, a glossary is provided on the last pages.
ARTHRITIS CONSUMER EXPERTS 910B RICHARDS STREET VANCOUVER BC V6B 3C1 CANADA T: 604.974-1366 F: 604.974-1377 WWW.ARTHRITISCONSUMEREXPERTS.ORG Arthritis Consumer Experts In Health Care and Research Decision-making
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationDiagnosis and management of rheumatoid arthritis
PRESCRIBING IN PRACTICE Diagnosis and management of rheumatoid arthritis GERALD TRACEY Early recognition and treatment of rheumatoid arthritis is the key to a more successful outcome. This article discusses
More informationAnti-Tumor Necrosis Factor (Anti-TNF)
Anti-Tumor Necrosis Factor (Anti-TNF) 110465 Anti-TNF.indd 1 9/20/16 9:01 AM s About your medicine Anti-tumor necrosis factor (anti-tnf) is a type of medicine called biologic agent that targets substance
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More informationRheumatoid Arthritis Fact Sheet
Rheumatoid Arthritis Fact Sheet This fact sheet is a summary of information found on ra.org.nz. Remember that each person is different and you should talk to your doctor about your disease and the best
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationInflammatory arthritis Shared Decision Making
Inflammatory arthritis Shared Decision Making DMARDs El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com Copyrights reserved Contents 1 2 3
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
More informationGolimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis
Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationSynoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22
DC IL12, IL23 chemokines, ECM, Co-stimulation IL17, IL22 IFNγ ± Macrophage peptidoglycan lipopolysaccharide heat shock proteins Th1/Th17 IL17 IL22 Cell contact, co-stimulation immune complexes acute phase
More informationBest practice management of musculoskeletal conditions in general practice A small group learning activity for practice teams
Best practice management of musculoskeletal conditions in general practice A small group learning activity for practice teams Best practice management of musculoskeletal conditions in general practice
More informationA. Correct! Nociceptors are pain receptors stimulated by harmful stimuli, resulting in the sensation of pain.
Pharmacology - Problem Drill 19: Anti-Inflammatory and Analgesic Drugs No. 1 of 10 1. are pain receptors stimulated by harmful stimuli, resulting in the sensation of pain. #01 (A) Nociceptors (B) Histamines
More informationThis is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors..
This is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/118272/ Version: Accepted
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationPharmacy Medical Necessity Guidelines:
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationRheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Examination of the dossier of medicinal products included on the reimbursement list for a period of 5
More informationClinical Policy: Tocilizumab (Actemra) Reference Number: ERX.SPMN.44
Clinical Policy: (Actemra) Reference Number: ERX.SPMN.44 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationEffective Health Care Program
Comparative Effectiveness Review Number 55 Effective Health Care Program Drug Therapy for Rheumatoid Arthritis in Adults: An Update Executive Summary Background Rheumatoid arthritis (RA), which affects
More informationACTEMRA (tocilizumab)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationThe BeSt way of withdrawing biologic agents
The BeSt way of withdrawing biologic agents C.F. Allaart 1, W.F. Lems 2, T.W.J. Huizinga 1 1 Department of Rheumatology, Leiden University Medical Center, Leiden; 2 Department of Rheumatology, Free University
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationHorizon Scanning Research & Intelligence Centre. Baricitinib for moderate to severe rheumatoid arthritis. May 2015 SUMMARY NIHR HSRIC ID: 5270
May 2015 Horizon Scanning Research & Intelligence Centre Baricitinib for moderate to severe rheumatoid arthritis SUMMARY NIHR HSRIC ID: 5270 This briefing is based on information available at the time
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abatacept, for rheumatoid arthritis, 789 Acetaminophen, for low back pain, 735 Acupuncture for fibromyalgia, 753 for low back pain, 738
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationHelpline No:
ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our
More informationMonoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs
John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationRheumatoid arthritis in adults: management
Rheumatoid arthritis in adults: management NICE guideline Draft for consultation, January 0 This guideline covers the diagnosis and management of rheumatoid arthritis in adults. Who is it for? Healthcare
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationNational Institute for Health and Clinical Excellence SCOPE. Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults
National Institute for Health and Clinical Excellence 1 Guideline title SCOPE Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults 1.1 Short title Rheumatoid arthritis 2
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationCimzia (certolizumab pegol)
DRUG POLICY BENEFIT APPLICATION Cimzia (certolizumab pegol) Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationAnnual European Congress of Rheumatology (EULAR) Madrid, Spain, June 2017
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW DATA SUGGEST NO INCREASED CANCER RISK FOR RA PATIENTS PRESCRIBED BIOLOGICAL DMARDS Reassuring findings may positively
More informationDr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria
Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationGrigorios T. Sakellariou, 1 Athanasios D. Anastasilakis, 2 Ilias Bisbinas, 3 Anastasios Gketsos, 4 and Charalampos Berberidis 1. 1.
ISRN Rheumatology Volume 2013, Article ID 907085, 4 pages http://dx.doi.org/10.1155/2013/907085 Clinical Study Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying
More informationClinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More information